Keyword: Advaxis

Prelude Therapeutics has completed a $60 million series B round as it looks to push its cancer work into the clinic.

Advaxis suffered the latest in a string of setbacks after the FDA requested chemistry, manufacturing and controls information. 

Almost a quarter of Advaxis' workforce is facing the chop as it scales back trials of its lead cancer immunotherapy, currently on clinical hold.

Sanofi hires ex-Roche executive as R&D chief, Advaxis names former Rosetta Genomics chief as CEO, and Urovant steals Allergan’s key urology VP.

Kenneth Berlin and Andres Gutierrez will join Advaxis as CEO and chief medical officer.

Regulatory officials took the action upon learning a cervical cancer patient developed respiratory failure and died after receiving the combination.

AZ CEO Pascal Soriot was said to be joining Teva as CEO, GSK poached Pfizer's medicinal sciences head, and Advaxis CEO O'Connor abruptly resigned.

Daniel O’Connor has resigned as CEO of Advaxis, which has put CBO Tony Lombardo in charge while it searches for a permanent successor.

Juno tapped Genentech alum Sunil Agarwal as new R&D chief, Merrimack promoted Onivyde scientist Daryl Drummond as head of research, and Mitch Gold leads the newly merged Alpine.

Advaxis and Amgen get an FDA OK to start testing their neoantigen cancer vaccine, partnered in a $540 million deal last year.